These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9510365)

  • 21. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical adjuvant therapy using mitomycin C.
    Islam MA; Bhuiyan ZH; Shameem IA
    Mymensingh Med J; 2006 Jan; 15(1):40-4. PubMed ID: 16467761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
    Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
    Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.
    Witjes JA; v d Meijden AP; Collette L; Sylvester R; Debruyne FM; van Aubel A; Witjes WP
    Urology; 1998 Sep; 52(3):403-10. PubMed ID: 9730451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C.
    Pavlotsky A; Eidelman A; Barak F; Walach N; Horn Y
    J Surg Oncol; 1995 Nov; 60(3):191-5. PubMed ID: 7475070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
    Milla P; Fiorito C; Soria F; Arpicco S; Cattel L; Gontero P
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):503-9. PubMed ID: 24442034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mitomycin-C 30 mg for 12 months versus Mitomycin-C 40 mg for 6 months in the prevention of superficial bladder carcinoma G1-G2].
    Vecchioli Scaldazza C
    Minerva Urol Nefrol; 1996 Dec; 48(4):203-6. PubMed ID: 9005589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
    Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
    Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
    Addeo R; Caraglia M; Bellini S; Abbruzzese A; Vincenzi B; Montella L; Miragliuolo A; Guarrasi R; Lanna M; Cennamo G; Faiola V; Del Prete S
    J Clin Oncol; 2010 Feb; 28(4):543-8. PubMed ID: 19841330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Oral tegafur plus mitomycin versus intravesical mitomycin alone in the prevention of recurrence in stage Ta bladder tumors].
    Server Pastor G; Rigabert Montiel M; Bañón Pérez V; Valdelvira Nadal P; Cao Avellaneda E; García Hernández JA; Pérez Albacete M
    Actas Urol Esp; 2003 Jun; 27(6):438-41. PubMed ID: 12918150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results.
    Milani C; Bassi P; Meneghini A; Garbeglio A; Zattoni F; Piazza N; Maruzzi D; Drago-Ferrante GL; Pagano F
    Urol Int; 1992; 48(2):154-6. PubMed ID: 1585510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
    Faraj K; Chang YH; Rose KM; Habermann EB; Etzioni DA; Blodgett G; Castle EP; Humphreys MR; Tyson Ii MD
    Can J Urol; 2019 Oct; 26(5):9922-9930. PubMed ID: 31629441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Liberati E; Dutto L; Verri C
    Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
    Minervini R; Felipetto R; Viganò L; Pampaloni S; Fiorentini L
    Urol Int; 1996; 56(4):234-7. PubMed ID: 8776821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
    Oosterlinck W
    Nat Rev Clin Oncol; 2011 Sep; 8(11):633-4. PubMed ID: 21912417
    [No Abstract]   [Full Text] [Related]  

  • 40. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
    Tapiero S; Helfand A; Kedar D; Yossepowitch O; Nadu A; Baniel J; Lifshitz D; Margel D
    Urology; 2018 Aug; 118():107-113. PubMed ID: 29792974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.